中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2009年
5期
804-806
,共3页
心肌梗死%辛伐他汀%肝素
心肌梗死%辛伐他汀%肝素
심기경사%신벌타정%간소
Myocardial infarction%Simvastatin%Heparin
目的 观察辛伐他汀联用低分子肝素钠治疗急性心肌梗死的临床疗效和安全性.方法 80例急性心肌梗死患者随机分为辛伐他汀联用低分子肝素钠治疗(联合组)40例,硝酸酯类药治疗(常规组)40例,观察治疗前后血清炎性因子水平、动态心电图及疗效指标.结果 常规组、联合组治疗后TC、TG、LDL、HDL-C、高敏C反应蛋白(hs-CRPs)、可溶性白细胞分化抗原40配体(sCD40L)水平均较治疗前下降(t=2.131,t=2.211,t=2.235,t=2.211,t=2.115,t=2.274,均P＜0.05);联合组治疗后hs-CRP、sCD40L下降水平较常规组明显(t=2.231,t=2.245,均P＜0.05);常规组IMT下降1.1%低于联合组3.4%(X2=4.01,P＜0.05);常规组治疗后斑块积分11.5%高于联合组斑块积分下降16.9%(X2=4.25,P＜0.05);联合组治疗后软斑数(7.7%)低于治疗前(28.2%)(X2=6.78,P＜0.01);联合组治疗后EDV、ESV、EF较治疗前下降明显(t=2.221,t=2.342,t=2.245,P＜0.05);常规组和联合组治疗后缺血发作次数、ST段最大下降幅度、ST段下降时间明显低于治疗前(t=2.731,t=2.781,t=2.785,t=2.781,t=2.815,t=2.874,均P＜0.01);联合组总有效率90.0%高于常规组67.4%(X2=4.25,P＜0.05).结论 辛伐他汀联用低分子肝素钠治疗急性心肌梗死疗效较好.
目的 觀察辛伐他汀聯用低分子肝素鈉治療急性心肌梗死的臨床療效和安全性.方法 80例急性心肌梗死患者隨機分為辛伐他汀聯用低分子肝素鈉治療(聯閤組)40例,硝痠酯類藥治療(常規組)40例,觀察治療前後血清炎性因子水平、動態心電圖及療效指標.結果 常規組、聯閤組治療後TC、TG、LDL、HDL-C、高敏C反應蛋白(hs-CRPs)、可溶性白細胞分化抗原40配體(sCD40L)水平均較治療前下降(t=2.131,t=2.211,t=2.235,t=2.211,t=2.115,t=2.274,均P＜0.05);聯閤組治療後hs-CRP、sCD40L下降水平較常規組明顯(t=2.231,t=2.245,均P＜0.05);常規組IMT下降1.1%低于聯閤組3.4%(X2=4.01,P＜0.05);常規組治療後斑塊積分11.5%高于聯閤組斑塊積分下降16.9%(X2=4.25,P＜0.05);聯閤組治療後軟斑數(7.7%)低于治療前(28.2%)(X2=6.78,P＜0.01);聯閤組治療後EDV、ESV、EF較治療前下降明顯(t=2.221,t=2.342,t=2.245,P＜0.05);常規組和聯閤組治療後缺血髮作次數、ST段最大下降幅度、ST段下降時間明顯低于治療前(t=2.731,t=2.781,t=2.785,t=2.781,t=2.815,t=2.874,均P＜0.01);聯閤組總有效率90.0%高于常規組67.4%(X2=4.25,P＜0.05).結論 辛伐他汀聯用低分子肝素鈉治療急性心肌梗死療效較好.
목적 관찰신벌타정련용저분자간소납치료급성심기경사적림상료효화안전성.방법 80례급성심기경사환자수궤분위신벌타정련용저분자간소납치료(연합조)40례,초산지류약치료(상규조)40례,관찰치료전후혈청염성인자수평、동태심전도급료효지표.결과 상규조、연합조치료후TC、TG、LDL、HDL-C、고민C반응단백(hs-CRPs)、가용성백세포분화항원40배체(sCD40L)수평균교치료전하강(t=2.131,t=2.211,t=2.235,t=2.211,t=2.115,t=2.274,균P＜0.05);연합조치료후hs-CRP、sCD40L하강수평교상규조명현(t=2.231,t=2.245,균P＜0.05);상규조IMT하강1.1%저우연합조3.4%(X2=4.01,P＜0.05);상규조치료후반괴적분11.5%고우연합조반괴적분하강16.9%(X2=4.25,P＜0.05);연합조치료후연반수(7.7%)저우치료전(28.2%)(X2=6.78,P＜0.01);연합조치료후EDV、ESV、EF교치료전하강명현(t=2.221,t=2.342,t=2.245,P＜0.05);상규조화연합조치료후결혈발작차수、ST단최대하강폭도、ST단하강시간명현저우치료전(t=2.731,t=2.781,t=2.785,t=2.781,t=2.815,t=2.874,균P＜0.01);연합조총유효솔90.0%고우상규조67.4%(X2=4.25,P＜0.05).결론 신벌타정련용저분자간소납치료급성심기경사료효교호.
Objective To observe the clinical effect and side-effect of low molecular weight beparin (LMWH) and simvastatin on patients with acute myocardial infarction(AMI). Methods 80 cases of AMI were randomly divided into simvastatin with low-molecular-weight heparin treatment (joint group) 40 cases and nitrates drug treatment( conventional group) 40 cases Au the patiants were observed before and after treatment for serum inflammatory factor,quantitative gated tomography,Holter and analysis of the effectbefore and after treatment. Results The conventional group and joint group after the treatment of TC, TG, LDL, HDL-C, hs-CRPs, CD40L levels were decreased than before treatment (t=2. 131, t = 2. 211, t = 2. 235, t = 2. 211, t = 2. 115, t = 2. 274, both P＜0. 05 ) ; the joint group after treatment bs-CRP, sCD40L significantly declined than conventional group (t = 2. 231, t = 2. 245, both P＜0. 05 ) ;conventional group of IMT dropped 1.1% lower than the 3.4% of the joint group ( X2 = 4. 01,P＜0. 05 ) ; conventional treatment group plaque score 11.5% higher than the combined group plaque score decreased 16. 9% (X2 =4. 25 ,P＜0. 05) ;joint group after treatment,a few soft spots(7. 7 %) lower than before treatment(28.2%) (X2 = 6. 78,P＜0. 01) ;the joint group of EDV,ESV,EF after treatment decreased significantly than before treatment (t =2. 221 ,t =2. 342 ,t = 2. 245, P＜0. 05) ; conventional treatment group and joint group after the number of ischemic attack, ST above the largest decrease, ST segment depression was significantly lower than the time before treatment(t=2. 731 ,t=2. 781, t=2. 785,t=2. 781, t=2. 815, t=2. 874, both P＜0. 01);joint total effective rate 90. 0% higher than the conventional group 67.4% (X2=4. 25,P＜0. 05 ). Conclusion Simvastatin combined with LMWH have good effect in the treatment of acute myocardial infarction.
